Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.